Core Viewpoint - Integra LifeSciences Holdings Corporation reported an earnings miss for Q1 2025, with adjusted EPS of 41 cents, falling short of estimates and showing a significant year-over-year decline of 25.5% [1][2][11] Financial Performance - Total revenues for Q1 2025 increased by 3.7% year over year to $382.7 million, slightly exceeding consensus estimates by 0.1% [3] - Organic revenue declined by 3.5% year over year, indicating challenges in core operations [3][11] - Gross profit decreased by 6% year over year to $194.4 million, with gross margin contracting by 526 basis points to 50.8% due to a 16.2% rise in the cost of goods sold [6] - Selling, general and administrative expenses rose by 9.5% to $181.5 million, while research and development expenses fell by 8.3% to $24.7 million [6] Segment Performance - Revenues in the Codman Specialty Surgical segment rose by 9.4% year over year to $280.7 million, although organic growth was down by 1.1% [4] - Neurosurgery sales within this segment fell by 4.7% organically, attributed to shipping holds [4] - Tissue Technologies revenues totaled $102 million, down 9.3% year over year, with notable declines in Private Label sales due to supply delays [5] Financial Position - At the end of Q1 2025, the company had approximately $239.1 million in cash and cash equivalents, down from $246.4 million at the end of Q4 2024 [8] - Cumulative net cash outflow from operating activities was $11.26 million, contrasting with cash inflows of $15.76 million a year ago [8] Guidance - For 2025, the company reaffirmed its revenue guidance of $1.650-$1.715 billion, indicating growth of 2.4%-6.5% [9] - Adjusted EPS forecast was reduced to a range of $2.19-$2.29 from a previous range of $2.41-$2.51 [9] - For Q2 2025, expected revenues are projected between $390-$400 million, reflecting a decline of 6.8%-4.4% [10] Strategic Insights - Despite the earnings miss, the company reported positive contributions from the Acclarent acquisition and double-digit growth in several product lines [12] - The company is focusing on advancing its Compliance Master Plan, expanding its international portfolio, and enhancing leadership [12]